DK1313485T3 - Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion - Google Patents

Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion

Info

Publication number: DK1313485T3
Authority: DK; Denmark
Prior art keywords: receptor antagonist; aldosterone receptor; cognitive function; improve cognitive; aldosterone
Prior art date: 2000-08-28

Application number

DK01964471T

Other languages

Danish (da)

English (en)

Inventor

Kenton N Fedde

Alfonzo T Perez

Joseph F Tooley

Original Assignee

Pharmacia Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-28

Filing date

2001-08-28

Publication date

2005-12-27

2001-08-28 Application filed by Pharmacia Corp filed Critical Pharmacia Corp

2005-12-27 Application granted granted Critical

2005-12-27 Publication of DK1313485T3 publication Critical patent/DK1313485T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK01964471T 2000-08-28 2001-08-28 Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion DK1313485T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US22873800P	2000-08-28	2000-08-28

Publications (1)

Publication Number	Publication Date
DK1313485T3 true DK1313485T3 (da)	2005-12-27

Family

ID=22858397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01964471T DK1313485T3 (da)	2000-08-28	2001-08-28	Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion

Country Status (10)

Country	Link
US (2)	US20020111337A1 (de)
EP (1)	EP1313485B1 (de)
JP (1)	JP2004507495A (de)
AT (1)	ATE306272T1 (de)
AU (1)	AU2001285318A1 (de)
CA (1)	CA2419256A1 (de)
DE (1)	DE60114027T2 (de)
DK (1)	DK1313485T3 (de)
ES (1)	ES2251505T3 (de)
WO (1)	WO2002017895A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005513024A (ja) *	2001-11-23	2005-05-12	アクゾ・ノベル・エヌ・ベー	グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療
NZ548754A (en) *	2002-04-26	2008-06-30	Schering Aktiengellschaft	Treatment of hypertension in women receiving hormone replacement therapy
TW200400816A (en)	2002-06-26	2004-01-16	Lilly Co Eli	Tricyclic steroid hormone nuclear receptor modulators
WO2004041288A1 (en) *	2002-11-05	2004-05-21	Schering Aktiengesellschaft	Hormone replacement therapy with drospirenone
US7786101B2 (en) *	2002-11-05	2010-08-31	Bayer Schering Pharma Ag	Cardiovascular protection using anti-aldosteronic progestins
JP2006508945A (ja) *	2002-11-05	2006-03-16	シエーリングアクチエンゲゼルシャフト	抗−アルドステロン性プロゲスチンを用いての心血管保護
JPWO2004060400A1 (ja) *	2003-01-06	2006-05-11	那波　宏之	上皮成長因子受容体を分子標的とする抗精神病薬
US7485094B2 (en) *	2003-09-30	2009-02-03	Smithmarks, Inc.	Methods of diagnosis using pulse volume measurement
EP2051696A2 (de) *	2006-08-18	2009-04-29	Morton Grove Pharmaceuticals, Inc.	Stabile flüssige levetiracetam-zusammensetzungen und verfahren
US20090265215A1 (en) *	2008-04-22	2009-10-22	Paul Bernhard Lindstrom	Methods and apparatus to monitor audience exposure to media using duration-based data
WO2012059594A1 (en) *	2010-11-04	2012-05-10	Bayer Pharma Aktiengesellschaft	Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
ES2618812T3 (es)	2011-01-20	2017-06-22	Merck Sharp & Dohme Corp.	Antagonistas del receptor mineralocorticoide
WO2012139495A1 (en)	2011-04-13	2012-10-18	Merck Sharp & Dohme Corp.	Mineralocorticoid receptor antagonists
WO2013055608A1 (en)	2011-10-13	2013-04-18	Merck Sharp & Dohme Corp.	Mineralocorticoid receptor antagonists
US9193717B2 (en)	2011-10-13	2015-11-24	Merck Sharp & Dohme Corp.	Mineralocorticoid receptor antagonists
EP2765859B1 (de)	2011-10-13	2017-01-18	Merck Sharp & Dohme Corp.	Mineralkortikoid-rezeptorantagonisten
AR091731A1 (es)	2012-07-19	2015-02-25	Merck Sharp & Dohme	Antagonistas del receptor de mineralocorticoides
WO2017083795A1 (en) *	2015-11-13	2017-05-18	Pietro Paolo Sanna	Methods and compositions for treating alcohol use disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3133012A (en) *	1961-06-28	1964-05-12	Universal Oil Prod Co	Combination catalytic reforming process
US3257390A (en) *	1963-06-12	1966-06-21	Merck & Co Inc	Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
IE51145B1 (en) *	1980-03-07	1986-10-15	Efamol Ltd	Pharmaceutical and dietary compositions
US4559332A (en) *	1983-04-13	1985-12-17	Ciba Geigy Corporation	20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
DE3506100A1 (de) *	1985-02-18	1986-08-21	Schering AG, 1000 Berlin und 4709 Bergkamen	1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2634376B1 (fr) *	1988-07-21	1992-04-17	Farmalyoc	Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
AU642066B2 (en) *	1991-01-25	1993-10-07	Nanosystems L.L.C.	X-ray contrast compositions useful in medical imaging
US5529992A (en) *	1992-04-21	1996-06-25	Curators Of The University Of Missouri	Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5747001A (en) *	1995-02-24	1998-05-05	Nanosystems, L.L.C.	Aerosols containing beclomethazone nanoparticle dispersions
CN100369927C (zh) *	1996-12-11	2008-02-20	G·D·瑟尔公司	9,11-环氧甾族化合物和其中有用的中间体的制备方法
DE19654609A1 (de) *	1996-12-20	1998-06-25	Schering Ag	Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
WO2000027380A2 (en) *	1998-11-06	2000-05-18	G.D. Searle & Co.	Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
UA74141C2 (uk) *	1998-12-09	2005-11-15	Дж.Д. Сірл Енд Ко.	Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
EP1382351B8 (de) *	1999-03-05	2006-03-08	G.D. Searle LLC.	Kombinationstherapie von Angiotensin-konvertierendem Enzymhemmer und Epoxy-steroidalem Aldosteron Antagonist zur Behandlung von kardiovaskulären Erkrankungen

2001
- 2001-08-28 WO PCT/US2001/026760 patent/WO2002017895A2/en active IP Right Grant
- 2001-08-28 DK DK01964471T patent/DK1313485T3/da active
- 2001-08-28 AT AT01964471T patent/ATE306272T1/de not_active IP Right Cessation
- 2001-08-28 DE DE60114027T patent/DE60114027T2/de not_active Expired - Fee Related
- 2001-08-28 AU AU2001285318A patent/AU2001285318A1/en not_active Abandoned
- 2001-08-28 EP EP01964471A patent/EP1313485B1/de not_active Expired - Lifetime
- 2001-08-28 US US09/941,206 patent/US20020111337A1/en not_active Abandoned
- 2001-08-28 ES ES01964471T patent/ES2251505T3/es not_active Expired - Lifetime
- 2001-08-28 JP JP2002522869A patent/JP2004507495A/ja not_active Withdrawn
- 2001-08-28 CA CA002419256A patent/CA2419256A1/en not_active Abandoned
2005
- 2005-02-25 US US11/067,426 patent/US20060058274A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2419256A1 (en)	2002-03-07
DE60114027T2 (de)	2006-07-13
DE60114027D1 (de)	2006-02-23
US20060058274A1 (en)	2006-03-16
US20020111337A1 (en)	2002-08-15
EP1313485B1 (de)	2005-10-12
AU2001285318A1 (en)	2002-03-13
ATE306272T1 (de)	2005-10-15
ES2251505T3 (es)	2006-05-01
JP2004507495A (ja)	2004-03-11
WO2002017895A3 (en)	2003-02-06
WO2002017895A2 (en)	2002-03-07
EP1313485A2 (de)	2003-05-28

Publication	Publication Date	Title
DK1313485T3 (da)	2005-12-27	Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
PT1349839E (pt)	2005-05-31	Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato
MXPA03004832A (es)	2004-05-04	Compuestos y sus usos.
DK1339678T3 (da)	2008-02-04	Selektive agonister til EP4-receptor til behandling af osteoporose
NZ548954A (en)	2009-07-31	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
YU45293A (sh)	1996-10-18	Morfolin i tiomorfolin tahikinin antagonisti receptora
MA28110A1 (fr)	2006-08-01	Antagonistes du recepteur d'acetylcholine muscarinique
SG163564A1 (en)	2010-08-30	Kinin antagonists for treating bladder dysfunction
MA27900A1 (fr)	2006-05-02	Antagonistes du recepteur de l'acetylcholine muscarinique
MA27901A1 (fr)	2006-05-02	Antagonistes du recepteur de l'acetylcholine muscarinique
HN2003000285A (es)	2004-11-23	Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
ATE311200T1 (de)	2005-12-15	Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
DK1117403T3 (da)	2004-04-13	MGLUR5-antagonister til behandling af smerte og angst
TW200503730A (en)	2005-02-01	Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
ECSP066486A (es)	2006-10-10	Antagonistas de receptores de acetilcolina muscarínicos ii
NO20034311D0 (no)	2003-09-26	CCR5-antagonister for behandling av AIDS
DE60203797D1 (de)	2005-05-25	Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
ATE407122T1 (de)	2008-09-15	Azadecalinmodulatoren des glucocorticoidrezeptors
NO20016246L (no)	2002-03-04	Selektiv iGluR5 reseptorantagonist for behandling av migrene
UY28646A1 (es)	2005-06-30	Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
UY28645A1 (es)	2005-06-30	Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
MXPA05007605A (es)	2005-09-30	Antagonista del receptor de androgenos.
AU1604001A (en)	2001-12-24	Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
DE60126134D1 (de)	2007-03-08	Crf-rezeptorantagonisten und diese betreffende verfahren
DK1146872T3 (da)	2006-10-16	Anvendelse af angiotensin II-receptorantagonister til behandling af akut myokardieinfarkt